Some Genzyme investors aren't willing to wait and see if the Big Biotech's board can be gradually lured to the bargaining table by Sanofi's slow motion M&A tactics. Frustrated by top management's refusal to sit down and see if they can work out a price, some shareholders are turning to the courts to see if they can prod Genzyme into opening up direct talks. Report